Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial

The death of a six-year-old girl following an experimental gene-editing therapy trial has cast a shadow over China's burgeoning biotechnology sector. Scientists have labeled the incident a tragedy, emphasizing the critical need to enhance safeguards within clinical trials, especially for novel gene-editing treatments involving pediatric patients.

This unfortunate event has sparked apprehension within the biotechnology industry, with fears that Chinese policymakers might impose stricter regulations. Such a move could curtail the regulatory flexibility that has been instrumental in China's rapid progress and competitive edge in developing frontier treatments. This flexibility has allowed for more agile, investigator-initiated clinical research.

“

I hope this tragedy does not have a lasting negative impact on China’s investigator-initiated clinical-research system, but there is a real risk of a regulatory backlash.

Wang Haoran, CEO of Neoland Biosciences, expressed his concerns, stating, "I hope this tragedy does not have a lasting negative impact on China’s investigator-initiated clinical-research system, but there is a real risk of a regulatory backlash." He noted that China's rapid advancement in several frontier areas has been partly due to this system's flexibility for early clinical exploration, creating a sense of urgency for competitors in the United States and Europe.

The case, detailed in a joint investigation by Retraction Watch and the journal Science, appears to reveal significant shortcomings in risk assessment, transparency, and institutional oversight. The girl, identified as Mei, died days after receiving a tailored therapy intended to correct a neurodevelopmental genetic mutation. The incident underscores the urgent necessity for robust safeguards, particularly in first-in-human gene-editing trials.

“

This case appears to reveal serious failures in risk assessment, transparency and institutional oversight. Stronger safeguards are clearly necessary, especially for first-in-human gene-editing treatments involving children.